Gothamist

A non-profit newsroom, powered by WNYC.

Gothamist

WNYC Listen Live

Donate

 

 

News

Candidate Giuliani's Drug (Consulting) Problem


By

Dave Hogarty

Published Dec 29, 2007

Modified Mar 7, 2008


Share

FacebookTwitterRedditEmail


Never miss a story

 Email address

By submitting your information, you're agreeing to receive communications from New York Public Radio in accordance with our Terms .


By

Dave Hogarty

Published Dec 29, 2007

Modified Mar 7, 2008


Share

FacebookTwitterRedditEmail


We rely on your support to make local news available to all

Make your contribution now and help Gothamist thrive in 2026. Donate today

Gothamist is funded by sponsors and member donations

purduepharma.jpgRudy Giuliani's good financial fortune derived from the formation of Giuliani Partners is leading to political misfortune, as yet another piece of lucrative business he conducted in the private sector has come back to haunt his candidacy. Recently, his involvement with Purdue Pharma--the producers of the painkiller OxyContin--has come under scrutiny.

Giuliani is being accused of using his high profile in the wake of 9/11, his background as a federal prosecutor, and his personal reputation in order to run interference against law enforcement for a drug company that was paying him handsomely. The top executives of Purdue Pharma eventually pleaded guilty to criminal charges for insufficiently warning the public of the potential for abuse of its highly profitable product as a street drug, and the company paid more than $600 million in fines.

Giuliani apparently found it very profitable to straddle the divide between government and his client, meeting with Asa Hutchinson, who was then the head of the DEA, after the agency began an investigation into Purdue. He stressed his credibility on the issue of fighting drug abuse by mentioning that he had donated $15,000 to the funding of a traveling DEA museum. He also assured Hutchinson that he was sending one of his top associates to oversee security improvements at Purdue's plant in New Jersey. Giuliani sent Bernard Kerik, who has proved to be a continuing embarrassment to his campaign.

Earlier this year, The Washington Post reported that while Giuliani was attempting to politically protect his client as OxyContin abuse was becoming a growing problem, the Justice Department was paying his firm $1.1 million to conduct a management review of the department's organized crime drug task force. One of that task force's responsibilities was to stem the illegal trade in OxyContin as a recreational narcotic.

(Image from ABC News blog The Blotter)

Tagged

abc

abc news

Asa Hutchinson

Bernard Kerik

dea

giuliani

Giuliani Partners

justice department

law enforcement

new jersey

news

oxycontin

rudy giuliani

The Washington

The Washington Post

washington

washington post


Dave Hogarty

Read more

Gothamist is funded by sponsors and member donations


Gothamist is funded by sponsors and member donations


MORE news

NYPD says man murdered his elderly aunt at their Bronx home

The man, 35, was charged with murder and assault.

By

Catalina Gonella

Published Nov 15, 2026 at 8:18 p.m. ET


A DJ survived the Brooklyn building collapse: His prized record collection did not

Omari Jack lost a massive collection of reggae records and memorabilia.

By

Michael Sol Warren

News

A DJ survived the Brooklyn building collapse: His prized record collection did not

Omari Jack lost a massive collection of reggae records and memorabilia.

By

Michael Sol Warren


New York's biggest trash dump is releasing even more methane than thought

By

Rosemary Misdary

NYPD fatally shoots driver on Belt Parkway following suspected kidnapping

By

Michael Sol Warren

Some in NY fret about being hit by the AI bus. Others are trying to board it.

By

Willow Higgins


Never miss a story

Catch up on the most important headlines with a roundup of essential NYC stories, delivered to your inbox daily.

Sign upEmail address

By submitting your information, you're agreeing to receive communications from New York Public Radio in accordance with our Terms .